TIDMGHH
RNS Number : 0166H
Gooch & Housego PLC
01 December 2020
For immediate release 1 December 2020
Gooch & Housego PLC
("Gooch & Housego", "G&H", the "Company" or the
"Group")
PRELIMINARY RESULTS FOR THE YEARED 30 SEPTEMBER 2020
Gooch & Housego PLC (AIM: GHH), the specialist manufacturer
of optical components and systems, today announces its preliminary
results for the year ended 30 September 2020.
Year ended 30 September 2020 2019 Change
Revenue (GBPm) 122.1 129.1 (5.5%)
------ ------ --------
Adjusted profit before tax
(GBPm)* 9.8 15.0 (35.1%)
------ ------ --------
Adjusted basic earnings per
share (pence)* 30.5p 46.8p (34.8%)
------ ------ --------
Statutory profit before tax
(GBPm) 5.4 6.0 (9.4%)
------ ------ --------
Basic earnings per share (pence) 15.1p 15.1p -
------ ------ --------
Total dividend per share (pence) - 11.5p (11.5p)
------ ------ --------
Net debt excluding IFRS16
(GBPm) 6.5 14.3 (7.8m)
------ ------ --------
Net debt (GBPm) 14.7 14.3 0.4m
------ ------ --------
-- adjusted figures exclude the amortisation of acquired
intangible assets, impairment of goodwill, adjustments to accrued
contingent consideration, non-underlying items being restructuring
costs, site closure costs, settlement of lease litigation, interest
thereon and interest on deferred consideration, together with the
related tax impact.
Operating & Strategic Key Points
-- Trading reflected a challenging global economic environment due to the COVID-19 pandemic.
-- G&H is proud of the way our staff responded.
-- Management actions contributed to a stronger second half.
These included ensuring all of our manufacturing sites in USA, UK
and China were able to operate at full capacity, compliant with all
relevant regulations and guidelines.
-- Overall demand for our technologies and capabilities was
robust. Medical diagnostics saw strong demand, whilst Industrial
lasers were below 'normalised' levels.
-- New products contributed record revenue of GBP16.9m during
FY2020 (FY2019: GBP13.5m). We continued to invest in our high
priority R&D targets.
-- G&H's plans to streamline our manufacturing are
progressing well and on track to deliver the previously announced
profitability.
-- There remains substantial long term growth potential for our
photonic technologies and system capabilities in all of our target
sectors.
Financial Key Points
-- Revenue of GBP122.1m, down by 5.5%
-- Adjusted profit before tax of GBP9.8m, down 35.1%, reflecting temporary disruption to G&H's manufacturing sites and lower demand in some subsectors due to the COVID-19 pandemic.
-- Improved net debt excluding IFRS16 of GBP6.5m, reflecting active cash management.
-- Year end order book of GBP92.4m, 0.8% higher than the same
time last year on a constant currency basis. Reflecting strong
demand for fibre optics, hi-reliability fibre couplers and our
A&D and Life Science capabilities. Industrial laser demand at
below 'normalised' levels. Improved demand for medical diagnostics,
in particular ventilator systems.
Mark Webster, Chief Executive Officer, commented:
" Our priority during the ongoing COVID-19 pandemic remains the
health and safety of our staff, customers and suppliers. We are
very proud of the way our staff have responded to this
unprecedented challenge.
"FY2020 profits were affected by temporary disruption to
manufacturing and lower demand in some subsectors due to the
COVID-19 pandemic. We have continued to invest in our high priority
R&D targets, been able to maintain a strong balance sheet and
have improved our liquidity levels.
"Our order book is robust and there remains considerable long
term potential for our photonic technologies and system
capabilities in all of our target sectors.
"The challenge of the pandemic has validated our long term
strategic goals of diversification and moving up the value chain.
We intend to vigorously pursue these goals through internal
investment and where appropriate, acquisitions."
For further information please contact:
Gooch & Housego PLC Mark Webster / Chris Jewell 01460 256440
Investec Bank plc (Nomad Christopher Baird / Patrick
& Broker) Robb / David Anderson 020 7597 5970
Mark Court / Sophie Wills
Buchanan / Charlotte Slater 020 7466 5000
Analyst meeting
A conference call for analysts will be held at 9.30am today, 1
December 2020. For further details please phone Buchanan on 020
7466 5000 or email g&h@buchanan.uk.com .
Expected Financial Calendar
Annual General Meeting 24 February 2021
Interim Results announcement June 2021
Financial Year End 30 September 2021
Preliminary announcement of results for December 2021
the year ended
30 September 2021
Chairman's Statement
Strategic Development
In 2020 we continued to execute our strategic objectives despite
the unprecedented challenges created by the pandemic for the
majority of the financial year. The year's trading also
demonstrated the benefits of the Group's ongoing strategy of
further diversification into the Aerospace & Defence and Life
Sciences markets, reducing its dependency upon its traditional
Industrial markets and making G&H a more balanced and resilient
business.
Our sustained investment in R&D and the close relationships
we have built with our customers supporting them with their next
generation product developments means we are well placed to benefit
from the long-term structural growth drivers in our markets. Our
photonic technologies and applications are providing our customers
with new solutions to their needs. In 2020 we made continued
progress in repositioning the Group to provide more complex
sub-assemblies and systems. These give more predictable and longer
term revenue streams and the opportunity for enhanced returns.
Operational Improvement
During the year the business has remained focused on its
operating costs to provide our customers with competitive offerings
and our investors with enhanced returns. The project announced in
March 2020 to migrate the manufacture of many of the Acousto-Optic
products produced at our Ilminster site to our Asian contract
manufacturing partner, the creation of an Acousto-Optic design and
engineering centre in Fremont, CA, allowing the creation of a UK
Precision Optics Centre of Excellence at our Ilminster site, and
the subsequent closure of our Glenrothes facility remains on track
to deliver on time and with the expected returns.
Our Response To The Pandemic
G&H's primary concern during the ongoing pandemic remains
the health and safety of our staff, customers and suppliers.
Progress on our established strategic and operational objectives
was achieved alongside our employees having to respond from the
second quarter of the financial year with great commitment and
agility to the developing pandemic. New policies and procedures
were implemented to allow the Group to operate effectively whilst
strictly complying with best practice guidelines. Additional
training was provided to our managers to help them lead their teams
in the new and unfamiliar circumstance of many team members working
from home. Some physical changes have had to be made to our
facilities to support enhanced social distancing. All of these
measures mean the Group is now well placed to withstand the
continuing operational disruption that the pandemic continues to
bring.
The hard work of our employees ensured we were able to keep our
facilities open for the majority of time and able to support our
customers' programmes. I am very proud of their achievement and on
behalf of the Board I would like to thank all our people for their
hard work and dedication in what has been a very challenging
year.
Trading Performance
The effects of the pandemic were felt most keenly in our
Industrial markets which were already impacted by cyclical downturn
and the effect of cross border trade disputes. Our Aerospace &
Defence market proved to be more resilient with the exception of
some of our commercial aircraft programmes. Life Sciences delivered
growth supported by strong trading from our recently acquired ITL
business. Thanks to swift adjustments to the cost base the Group
continued to be profitable and cash generative despite the impact
of the pandemic. Order intake recovered well in the latter part of
the financial year and we enter the new trading period with an
order book 0.8% higher in constant currency than at September 2019
which provides an important underpin to the Group's revenues for
FY2021.
Dividends
In light of the increased global economic uncertainty and in
accordance with the Board's priority of conserving cash and
managing the Group in a prudent manner through that uncertainty, a
dividend will not be declared in respect of FY2020.
The Board will review its position for the current financial
year with the intention of reinstating its long term progressive
dividend policy as soon as it is appropriate to do so.
The Board
In December 2019 we were shocked and saddened by the death of
our Audit Committee Chairman, David Bauernfeind. Since joining the
Board in 2017, David had provided invaluable support to the
business and his significant contribution to G&H is sadly
missed.
In May 2020 we welcomed Louise Evans to the Board in the role of
Non-Executive Director and Chair of the Audit Committee. She brings
extensive experience from her strategic leadership roles in both
listed and privately owned technical engineering groups. Louise has
substantial expertise in the areas of financial management and
M&A as well as the implementation of internal control and risk
management frameworks. We are enjoying working with her.
Looking Ahead
Whilst the macroeconomic environment remains uncertain we enter
the new financial year with a solid order book, cutting edge
products and technologies and an increasingly competitive cost
base. Our strategy is making G&H a better, more balanced
business, and subject to the macroeconomic background, I am
confident t he Group is well positioned to deliver material
progress in FY2021 and indeed beyond .
Gary Bullard
Chairman
1 December 2020
Chief Executive Officer's Statement
FY2020 Performance
During the financial year 2020 G&H achieved revenue of
GBP122.1m, representing a decrease of 5.5% over previous year or
excluding foreign exchange, a decline of 5.4%. Adjusted profit
before tax was GBP9.8m, a decline of 35.1%.
Overall demand for our technologies and capabilities was robust.
There was an improved level of demand for medical diagnostics.
Industrial lasers, the part of our portfolio most exposed to the
wider economy, was below 'normalised' levels.
Trading reflected a challenging economic environment due to the
COVID-19 pandemic.
Our primary concern during the ongoing pandemic remains the
health and safety of our staff, customers and suppliers. Wherever
possible our employees are working from home and for those that
need to work at our manufacturing sites we have implemented a range
of new health and safety measures to ensure that we rigorously meet
social distancing and cleanliness requirements and all other
relevant guidelines and regulations.
In the second quarter of the financial year two of our six US
sites were temporarily shut down, due to state wide 'stay at home'
orders. All of our five sites in the UK remained open, though
Torquay, our largest site, operated at reduced capacity in order to
comply with social distancing regulations.
We are very proud of the way that our staff responded to these
unprecedented challenges.
In the latter part of the year G&H returned to full
manufacturing capacity at all of our sites in the UK, USA and
China. Action taken to reduce the Group's cost base and headcount
had a positive impact on our second half performance.
Throughout the financial year we have closely controlled the
cash resources of the business. As a result, the Group remains in a
sound financial position with a strong balance sheet. Liquidity
levels improved during the period, supported by a $10m extension to
the Group's revolving credit facility, secured in April 2020,
taking the total to $50m.
G&H has entered the new financial year with a solid order
book. As at 30 September 2020 it stood at GBP92.4m (30 September
2019: GBP94.4m), 2.2% lower than the same period previous year, or
an increase of 0.8%, excluding the impact of foreign exchange.
The year end order book reflects strong demand for fibre optics,
hi-reliability fibre couplers for undersea cables and our A&D
and life science capabilities. Demand improved for medical
diagnostic equipment, in particular for ventilator systems.
Industrial laser demand remains at below 'normalised' levels,
though there has been a sustained improvement in the semiconductor
subsector.
Industrial laser demand will return to longer term growth
through technical innovation in end market applications such as 5G,
AI and new laser-based manufacturing techniques, though the exact
timings are hard to predict.
Our long term strategic commitment to diversification and moving
up the value chain has been validated by the COVID-19 pandemic and
has been instrumental in partially offsetting its impact. The Group
has continued to invest in the business during the financial year,
in line with these long term strategic goals.
New products from R&D contributed record revenues in FY2020
of GBP16.9m (FY2019: GBP13.5m). G&H was able to make further
R&D investment in areas we identified as having high growth
potential for our photonic technologies, such as the latest
industrial laser systems, 'harsh environment' sensing, unmanned
aerial vehicles ('UAVs"), novel aerospace and defence programmes,
space satellite communications, laser surgery and medical
diagnostics.
In line with our strategic commitment to improving manufacturing
efficiency, customer service and capacity we have continued to move
forward with streamlining our manufacturing, as announced in March
2020. This is progressing well and on schedule to complete by the
end of the calendar year 2021, with the expected improvement in
profitability unchanged.
Strategic Goals
We remain committed to our twin strategic goals of further
diversification and moving up the value chain. This enables us to
more fully exploit our photonic technologies and system
capabilities.
Aerospace & Defence ("A&D") and life sciences provide a
counter balance to the industrial laser business. These sectors
both have high quality and compliance barriers to entry and as
markets move towards greater use of photonic technologies, G&H
is increasingly well placed to serve customers in these
markets.
Our aim remains to achieve a broadly equal split between the
three market sectors. In FY2020 A&D represented 33.9% (FY2019:
34.2%) of G&H's revenue and life sciences 21.2% (FY2019:
18.7%), which represents considerable progress over the last few
years.
G&H will continue to pursue our twin strategic objectives
through internal investment and where appropriate,
acquisitions.
Acquisitions
ITL is a UK based specialist in the design, development and
manufacture of high quality medical devices. This acquisition has
been a significant factor in G&H more than doubling the size of
its life science business over the last two years. ITL's portfolio
consists entirely of systems based products and that systems
capability enables G&H to present an enhanced offering of
photonic systems to our customers that will form a durable platform
for further growth in the life science sector.
ITL was acquired in August 2018. Its performance has exceeded
expectations and it has fully achieved its second year earn-out
payment for the year ended 30 September 2020.
Research and Development ("R&D")
There has been continued benefit from concentrating our R&D
resources on fewer higher return projects that the Group has
identified as offering the highest growth potential for our
photonic technologies and system capabilities. During FY2020 we
introduced 40 new products and delivered record new product
revenue.
G&H continues to work with our industrial laser and
industrial laser system partners on the latest ultra-fast precision
lasers. We recently signed a multi-year partnership contract in
order to develop the next generation of extreme UV lithography
lasers that will be used in the production of atomic level
nanoelectronics.
We have capitalised on our expertise in lasers to provide
solutions for 'harsh environment' sensing. The 'laser engine'
technology developed for wind detection in wind turbines and oil
pipeline security is now being utilised in development of a wider
range of security applications.
Unmanned aerial vehicles ("UAVs") have a variety of commercial
and military uses. Our expertise in the design, engineering and
manufacturing of bespoke complex optical arrays in the IR spectrum
for the UAVs' imaging and communication systems represents a rich
vein of opportunity for the Group.
G&H's laser based satellite communication system has passed
rigorous pre-flight tests for commercial satellites and will be
launched in the near future. We continue to work on European and UK
space agency funded work, as well other commercial programmes.
There is substantial opportunity to expand similar technology into
small satellite constellations and near space UAVs.
We have a number of ongoing A&D programmes in the US and
Europe which operate under high level security or confidentiality
restrictions. At our Boston, MA site we have built on the leading
edge development work for existing programmes enabling us to
acquire further contracts.
Our ITL business has a range of leading edge medical diagnostic
R&D collaborations. By combining G&H's core photonic
technologies with ITL's system capabilities we have been able to
work on new types of opportunities for our medical diagnostic
customers.
Streamlining of G&H's Manufacturing Base
As part of our move towards improving manufacturing efficiency,
customer service and capacity, we announced in March 2020 that we
will streamline our manufacturing operations.
In the first instance this will be achieved by outsourcing
Acousto Optic (AO) Q-switch manufacturing to a contract
manufacturer in Asia and creating an AO engineering and design hub
at our Fremont, CA site. Secondly, we are establishing a UK
Precision Optic (PO) hub for the UK in Ilminster, Somerset by
moving our specialist PO manufacturing from Glenrothes, Scotland
and then closing the site. The restructuring remains on track to
complete by the end of the calendar year 2021 and the expected
financial benefits are unchanged.
Our manufacturing sites are organised within three manufacturing
centres based around technical areas of excellence. Each
manufacturing centre is led by an experienced manufacturing head
whose role is to ensure best practice is shared, there is process
harmonisation and optimal allocation of resource.
We are in year two of a three year programme of upgrading and
harmonising our financial and business systems, which are designed
to support and enable improved performance in the manufacturing and
commercial functions. This project is on track and has already
delivered tangible benefits.
Markets and Applications
Industrial - 44.9% of FY2020 Group Revenue
The industrial division services a diverse range of industrial
applications aligned to our world class photonic technologies. It
splits into four distinct areas, industrial lasers, optical
communications, 'harsh environment' sensing and scientific
research.
Our industrial division declined by GBP6.0m or 9.9% compared
with the previous year.
Industrial lasers went through a cyclical downturn in FY2019 on
the back of a strong FY2018. As the area of our business most
exposed to the wider economy there was no return to demand growth
in FY2020 due to the COVID-19 pandemic. In the latter part of the
year demand has picked up in certain subsectors, most notably
semiconductors.
Longer term technological progress in end market applications
will drive demand growth in the high innovation, higher margin
section of the market. We are actively engaged with our industrial
laser partners in developing the next generation of precision
lasers. Outsourcing lower innovation products to a contract
manufacturer in the Far East will enable us to compete more
effectively in this subsector.
Hi-reliability fibre couplers for undersea cables are undergoing
a multi-year growth phase driven by the well capitalised 'Silicon
Valley' companies laying their own undersea cable networks. G&H
has continued to invest in improving capacity for this section of
business as we believe there will be good growth dynamics for the
foreseeable future.
'Harsh environment' sensing has performed well and we have
picked up new orders for our 'laser engines' used for directional
sensing in wind farms and security related to oil pipelines and
other related areas.
Scientific research includes high profile 'Big Science' projects
such as supplying critical components to the world's most powerful
laser system at the National Ignition Facility at Lawrence
Livermore National Laboratory ("LLNL") in Northern California and
its European equivalent, Commissariat a l'energie atomique et aux
energies alternatives ("CEA") in Bordeaux, France. G&H is a
primary supplier to these facilities and this represents a
profitable and prestigious part of our industrial business.
Aerospace & Defence - 33.9% of FY2020 Group Revenue
G&H is able to bring together a wide range of photonic
capabilities that very much represent the "direction of travel" in
this sector. These include target designation, range finding, ring
laser and fibre optic gyroscopic navigational systems, infra-red
and RF counter measures, periscopes and sighting systems for
armoured vehicles, opto-mechanical sub-systems for UAVs and space
satellite communication systems.
Delivering product quality, reliability and high performance in
harsh environments is essential in the A&D arena and this very
much plays to G&H's strengths. Our customers include the main
tier one US and European A&D companies.
A&D revenue declined by GBP2.8m or 6.4% compared with the
previous year.
During FY2020 we were able to continue to deliver on a number of
high profile US contracts and win further business from existing
and new contracts. Our revenues in the UK suffered from contract
phasing issues. Though all of our tier one A&D customers
continued to operate, the effect of working from home meant that
many of the demanding, 'high hurdle' quality, compliance and supply
chain aspects inherent in this sector took longer to navigate than
usual and slowed down the business momentum in this sector.
G&H has exited FY2020 with a record A&D order book in
the US and a much improved order book in the UK and Europe as a
result of the determined work by our teams throughout the year in
order to take advantage of good underlying demand for our
capabilities.
We expect to have our laser based satellite communication system
in space during FY2021, having passed all of the rigorous
pre-flight operating tests. The use of fibre optic lasers to
transmit information means satellite communication systems are more
efficient, robust and substantially lighter. We believe this will
lead to further utilisation of our technology in small satellite
constellations and near space UAVs.
Life Sciences / Biophotonics - 21.2% of FY2020 Group Revenue
Life Science revenues grew by GBP1.8m or 7.6% compared with the
previous year.
Our medical diagnostic system business grew strongly during the
year and benefited from increased demand for our products as a
result of the COVID-19 pandemic. This was particularly true for a
product manufactured by ITL which is designed to improve
respiratory function and oxygen uptake, as part of a ventilator
system for patients in critical care. It is available globally, but
has greatest traction in the US.
G&H's principal photonic applications in life sciences are
optical coherence tomography ("OCT"), laser surgery and laser
microscopy. OCT is widely used in ophthalmology for 3D retinal
scanning and G&H has a market leading position in this area.
Similar technology is also applied to cardiovascular and cancer
disease detection systems for US based medical diagnostic
companies.
In contrast to our medical diagnostic business there was a
reduction in the number of non COVID-19 medical procedures. This
resulted in lower OCT business and a sharp reduction in the number
of procedures using medical lasers, in particular for cosmetic
procedures. In the latter part of the year demand for our OCT
diagnostics and critical components for medical lasers started to
demonstrate a return to demand growth.
Outlook
In the short term, there is significant global economic
uncertainty due to the COVID-19 pandemic, but G&H's order book
remains robust and a testament to the benefits of a diversified
portfolio.
During FY2020 a number of management actions have enabled the
Group to build in greater resilience to our business. All of our
manufacturing sites in the US, UK and China are open, able to
operate at full capacity and are compliant with all national and
local health and safety requirements. Our manufacturing site at
Torquay is now able to operate at full capacity while complying
with social distancing regulations due to infrastructure and
process improvements undertaken since the start of the pandemic.
G&H's six US sites are now all classified as fully or mainly
exempt, as they produce products deemed essential or vital for
national security.
G&H's plan to streamline its manufacturing is on track and
will deliver the improvements in profitability outlined in the
March 2020 announcement. Our cost base and headcount has been
reduced and is now in line with the demands of the current working
environment. Going forwards, we will continue to review further
improvements to the Group's operations.
The Company remains in a sound financial position, with a strong
balance sheet having improved its liquidity levels through FY2020
and into the start of the current financial year.
New products delivered a record contribution in FY2020 and we
will continue to invest in those areas identified as delivering the
highest return for our photonic technologies and system
capabilities. There remains substantial long term growth potential
for our photonic technologies and system capabilities in all of our
target sectors.
Our commitment to our strategic objectives of diversification
and moving up the value chain has been validated and will provide a
robust platform for future growth. G&H intends to continue to
vigorously pursue this policy through internal investment and where
appropriate, further acquisitions.
Subject to the short term global economic environment, the Board
remains confident that G&H is well positioned to deliver
material progress in FY2021 and substantial long term growth.
Mark Webster
Chief Executive Officer
1 December 2020
Performance Overview
Overview
The Group's trading performance in the year reflected the impact
of the pandemic on demand in our Industrial and Commercial
Aerospace markets and some temporary closures of our facilities.
Revenue and underlying profit before tax for the year were,
however, marginally ahead of management's revised expectations
following the advent of the pandemic, reflecting a faster than
expected recovery to full operational capacity in the second half
of the year.
Group revenue for the year totalled GBP122.1m. This represents a
reduction of GBP7.0m, or 5.5% over the previous year. On a constant
currency basis, revenues declined by 5.4%.
The Group's adjusted profit before tax amounted to GBP9.8m
(2019: GBP15.0m) and represented a margin of 8.0% (2019: 11.6%).
Statutory profit before tax was GBP5.4m compared with GBP6.0m in
the prior year. Adjusted profit before tax is a key alternative
performance measure by which the Board evaluates the Group's
performance as it better represents the underlying trading of the
Group with restructuring costs, acquisition and disposal items
excluded from this measure. Further details of alternative
performance measures are provided later in this review.
Cash performance for the year was good with the business
generating GBP21.6m of cashflow from operating activities. In April
2020 the Group entered in to an agreement to increase its revolving
credit facility from $40m to $50m, extending the maturity date from
August 2021 to April 2023.
Revenue
REVENUE
---------------------------------------- ------ -------- --------
2020 2019
---------------- ------------------
Year ended 30 September GBP'000 % GBP'000 %
------------------------------ -------- ------ -------- ------
Industrial 54,811 44.9% 60,854 47.1%
------------------------------ -------- ------ -------- ------
A&D 41,390 33.9% 44,203 34.2%
------------------------------ -------- ------ -------- ------
Life Sciences / Biophotonics 25,894 21.2% 24,076 18.7%
------------------------------ -------- ------ -------- ------
Group Revenue 122,095 100% 129,133 100%
------------------------------ -------- ------ -------- ------
Revenue for the year totalled GBP122.1m, compared with GBP129.1m
in the prior year. In the first quarter of the trading year our
Industrial business segment was impacted by the ongoing weaker
demand in its end markets and then from the second quarter by the
COVID-19 pandemic. Industrial revenue declined by 9.9%, in both
absolute and constant currency terms, from GBP60.9m last year to
GBP54.8m this year. However, the sector's H2 revenues grew compared
to the first six months of the year supported by the continuing
ramp up in revenues from its telecoms markets.
In A&D important milestones were achieved on US development
programmes allowing progression to the production stage of the
contracts but overall revenues declined year on year by 6.4% (6.1%
at constant currency) from GBP44.2m to GBP41.4m, primarily due to
the completion of programme deliveries to customers of our St Asaph
facilities prior to new programmes reaching their production phase
in the second half of FY2021.
Our Life Sciences / Biophotonics business delivered year-on-year
growth of 7.6% (7.7% at constant currency). Our ITL business saw
strong demand for components used in respirator systems, more than
offsetting a downturn in the medical laser market as a result of
the pandemic. Life Sciences / Biophotonics revenue increased in
absolute terms from GBP24.1m to GBP25.9m.
Operating Costs
In response to the challenging trading conditions we took a
number of actions to reduce the Group's cost base. Group headcount
decreased from 984 at 30 September 2019 to 902 at 30 September
2020. Headcount reductions were partially attributable to the
restructuring project described later in this review, but other
reductions were made to adjust to reduced trading volumes. Labour
costs were also mitigated as some employees were furloughed,
primarily at our Torquay site which temporarily ran at reduced
capacity. There are currently no employees furloughed and Torquay
is back operating at full capacity. Actions were also put in place
to reduce discretionary spend such as travel and exhibitions which
also contributed to the decrease in operating costs.
Research and Development (R&D)
The Group continued to invest for the future with R&D spend
at 6.5% of revenue, which was in line with prior year. R&D
spend in the period was GBP8.0m. There were 40 new products
released in FY2020, together with five new patents granted.
Important developments were completed in the fields of space
satellite communications and sighting systems for armoured
vehicles. The Group capitalised GBP0.5m of development expenditure
in the year (2019: GBP0.7m).
Alternative Performance Measures
Alternative performance measures are presented in these
financial statements as management believe they provide investors
with a means of evaluating the performance of the Group on a
consistent basis. These alternative performance measures exclude
the impact of non-underlying items on the Group's financial
results. The Group's alternative performance measures and their
reconciliation to IFRS measures are shown in the table below. In
addition to the measure shown in the table below, the Group
presents Adjusted Profit Before Tax which is Adjusted Operating
Profit less Adjusted net Finance Costs.
Non-Underlying Items
Statutory operating profit was GBP6.3m (2019: GBP8.4m) and
statutory profit before tax was GBP5.4m (2019: GBP6.0m).
Non-underlying items are presented separately as the Directors
believe that they require separate disclosure on account of their
nature and size in order to provide a clear and consistent
presentation of the Group's underlying business performance.
Adjusted operating profit declined by 31% to GBP11.2m (2019:
GBP16.3m) and adjusted profit before tax by 35% to GBP9.8m (2019:
GBP15.0m) after excluding net charges of GBP4.4m (2019: GBP9.1m) in
respect of non-underlying items. These comprised restructuring and
site closure costs of GBP2.6m (FY2019: GBP1.0m), charges in respect
of acquisitions and the amortisation of acquired intangible assets
of GBP2.7m (2019: GBP9.9m) and a non-underlying credit of GBP1.2m
(2019: GBPnil) in respect of a legal judgement in our favour
associated with the lease of our Fremont facility.
The restructuring costs incurred in the year related to expenses
arising from the project to establish the Ilminster facility as our
UK Precision Optics Centre of Excellence and the resultant closure
of our Glenrothes facility. This project is described more fully in
the Operations section of this review. The costs recorded in the
period principally comprised redundancy costs and the write downs
of both tangible fixed assets and inventories of products which
will be discontinued at the completion of the project.
In March 2020 long running litigation with the landlord of our
Fremont facility was finally concluded and G&H was awarded a
total of $3.6m comprising damages, reimbursement of our costs and
interest arising from the landlord's non-performance in respect of
the lease and this amount was received in full in June 2020. The
reimbursement of costs and interest received of GBP1.2m was treated
as a non-underlying credit in the income statement whilst the
damages element of the award was credited against the right of use
asset held on the balance sheet.
RECONCILIATION OF ADJUSTED PERFORMANCE MEASURES
------------------------------------------------
Operating Net finance Taxation Earnings
profit costs per share
------------------------- ------------------ ------------------ ------------------ ----------------
Year ended 30 2020 2019 2020 2019 2020 2019 2020 2019
September GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 pence Pence
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Reported 6,334 8,408 (942) (2,456) (1,610) (2,191) 15.1p 15.1p
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Amortisation
of acquired
intangible assets 2,676 3,690 - - (397) (676) 9.1p 12.1p
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Restructuring
and site closure 2,609 973 - - (392) (206) 8.9p 3.0p
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Settlement of
lease dispute (410) - (818) - 271 - (3.8)p -
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Impairment of
goodwill - 6,258 - - - (921) - 21.4p
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Adjustment to
accrued contingent
consideration - (3,075) - - - 662 - (9.7)p
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Interest on
deferred consideration - - 303 1,218 - - 1.2p 4.9p
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Adjusted 11,209 16,254 (1,457) (1,238) (2,128) (3,332) 30.5p 46.8p
------------------------- -------- -------- -------- -------- -------- -------- ------- -------
Interest
The net underlying interest expense of GBP1.5m (2019: GBP1.2m)
increased by GBP0.2m. This was largely due to the adoption of
IFRS16 from 1 October 2019 which added GBP0.4m to the Group's
interest charge.
Tax and Earnings Per Share
The tax charge for the year was GBP1.6m (2019: GBP2.2m) with an
underlying tax charge of GBP2.1m (2019: GBP3.3m) after excluding a
credit on items excluded from underlying profit of GBP0.5m. This
resulted in an underlying effective tax rate of 21.8% (2019:
22.2%), a marginal reduction on the prior year as we were able to
increase the utilisation of historical tax losses in our US
operations. The rate reflects a combination of the varying tax
rates applicable throughout the countries in which the Group
operates, principally the UK and the USA.
GROUP EARNINGS PERFORMANCE
----------------------------------- -------- -------- ----------
All amounts in GBP'000 Adjusted Reported
--------------------
Year ended 30 September 2020 2019 2020 2019
------------------------- -------- -------- -------- --------
Operating profit 11,209 16,254 6,334 8,408
------------------------- -------- -------- -------- --------
Net finance costs (1,457) (1,238) (942) (2,456)
------------------------- -------- -------- -------- --------
Profit before taxation 9,752 15,016 5,392 5,952
------------------------- -------- -------- -------- --------
Taxation (2,128) (3,332) (1,610) (2,191)
------------------------- -------- -------- -------- --------
Profit for the year 7,624 11,684 3,782 3,761
Basic earnings per
share (p) 30.5p 46.8p 15.1p 15.1p
------------------------- -------- -------- -------- --------
Basic underlying earnings per share decreased to 30.5p (2019:
46.8p).
Balance Sheet
The Group's total equity at the end of the year was GBP113.4m,
an increase of GBP0.5m over the prior year. This comprised an
increase of GBP2.0m from retained earnings, a GBP0.3m increase from
adjustments to reserves for long term incentives and a net
reduction of GBP1.8m from foreign exchange and other movements.
Additions to tangible and intangible fixed assets totalled
GBP6.8m (2019: GBP7.5m), equivalent to 1.08 times owned asset
depreciation and amortisation (2019: 1.43 times). The most
significant additions were new state of the art precision optic
cutting and polishing equipment located in our newly formed UK
centre of excellence in Ilminster. We made further investments in
our IT system with our Keene, St Asaph and Baltimore businesses now
migrated on to the Group's core ERP systems.
For the full year there was a GBP4.7m inflow from working
capital (2019: GBP6.6m outflow). Within working capital, inventory
decreased to GBP30.6m from GBP33.3m at the beginning of the year
reflecting lower business volumes and our continuing work to
improve our demand forecasts on which our manufacturing build plan
is based.
Trade and other receivables at year end were GBP26.3m, a
reduction of GBP6.9m compared with the prior year. The reduction
was due to the lower trading levels and a continued strong focus on
collections, although we are experiencing continued pressure from
many of our larger customers for extended payment terms.
Net interest (excluding IFRS 16 interest and interest received
on the legal settlement) and tax paid reduced to GBP2.2m from
GBP2.4m in the prior year.
IFRS 16 Leases
The Group implemented IFRS 16 leases with effect from 1 October
2019. On adoption of the standard the Group recognised right of use
assets of GBP9.6m and a lease liability of GBP9.4m. The impact on
the income statement in the year has been to increase underlying
operating profit by GBP0.3m and interest expense by GBP0.4m.
Cash and Net Debt
Cash balances at 30 September 2020 were GBP19.7m, compared with
GBP17.5m in the prior year. Net cash flows from operating
activities totalled GBP20.4m, compared with GBP11.6m last year,
supported by the lower levels of working capital year-on-year.
During the year net debt excluding lease liabilities decreased by
GBP7.8m to GBP6.5m, of which GBP1.2m was as a result of exchange
rate movement on the Group's US$ denominated borrowings. IFRS 16
lease liabilities added a further GBP8.2m bringing the Group's
reported net debt to GBP14.7m at the year end.
As at 30 September 2020, available undrawn committed and
uncommitted debt facilities totalled $36m.
MOVEMENT IN NET DEBT
All amounts in GBPm Net Debt
Gross Exc IFRS16 Net
Cash Bank Borrowings Lease Liabilities Debt
----------------------------- ------ ---------------- ------------ -------------------- -------
At 1 October 2019 17.5 (31.8) (14.3) - (14.3)
Adoption of IFRS16 - - - (9.4) (9.4)
Operating cash flows 16.8 - 16.8 - 16.8
Debt repayments (4.3) 4.3 - - -
Lease repayments (1.6) - (1.6) 1.6 -
Acquisitions (deferred
consideration) (4.8) - (4.8) - (4.8)
Net capital expenditure (6.4) - (6.4) - (6.4)
Working capital 4.7 - 4.7 - 4.7
Interest, tax and dividends (3.4) - (3.4) - (3.4)
Legal dispute settlement 1.6 - 1.6 - 1.6
Non cash movements - 0.1 0.1 (0.8) (0.7)
Exchange movement (0.4) 1.2 0.8 0.4 1.2
----------------------------- ------ ---------------- ------------ -------------------- -------
At 30 September 2020 19.7 (26.2) (6.5) (8.2) (14.7)
----------------------------- ------ ---------------- ------------ -------------------- -------
Funding and Liquidity
In April 2020 the Group entered into an agreement to increase
its revolving credit facility from $40m to $50m, taking the
maturity date out from August 2021 to April 2023.
Borrowings from the Group's revolving credit facility are drawn
at the Group level and lent to the operating subsidiaries.
The main financial covenants in the revolving credit facility
restrict net debt to below 2.5 times underlying EBITDA, and EBITDA
is required to cover net interest costs (excluding IFRS 16
interest) by 4.5 times.
As at 30 September 2020, net debt : underlying EBITDA was 0.4
(2019: 0.6) and interest cover was 10.8 (2019: 15.4).
The rationale for preparing the financial statements on a going
concern basis is set out below.
Operations
As announced in March 2020, the Group has launched a significant
restructuring project to streamline its Acousto-Optic (AO) and
Precision Optic (PO) manufacturing facilities. An AO hub is being
created at our Fremont, California site which combines the AO
capabilities of our Fremont and Ilminster facilities. Fremont will
lead the Group's AO technology roadmap. In support of this approach
we entered in to an agreement to outsource much of our AO
manufacturing currently undertaken by our Ilminster facility to an
established contract manufacturer in South East Asia. These plans
enable us to consolidate design, engineering and R&D resources
and to continue to provide high quality, cost competitive products
to the industrial laser market.
As part of this same project the Group is establishing a single
UK PO hub at our Ilminster facility fashioned from our two current
PO sites at Ilminster and Glenrothes. As part of this plan we are
transferring Glenrothes PO manufacturing resources and capabilities
into Ilminster and the Glenrothes site will be closed at the end of
the current calendar year. The project is expected to be fully
complete by the end of 2021 financial year. The total investment is
expected to be c. GBP5m across FY2020 and FY2021 and the one off
income statement impact has been excluded from adjusted profit
before tax. Total non-underlying charges on the project in FY2020
were GBP2.4m. Savings are expected to build over time, and to
achieve a positive benefit in the second half of FY2021 and an
annualised benefit of c. GBP1.25m by FY2022.
We have now completed the roll out of our Syspro ERP/MRP system
to all of the Group's sites with the exception of ITL which had
recently upgraded to an Epicor system shortly prior to the
acquisition of the business by the Group in 2018. We have developed
a suite of business reports based upon data warehousing which has
significantly enhanced the quality of information available to the
management team.
COVID-19 Pandemic
As a result of the pandemic we implemented a range of measures
to keep our employees safe, to continue to support our customers'
programmes and to protect the financial position of the business.
In the early stages of the pandemic whilst many of our customers'
facilities were partially or fully closed and we were in the
process of making alterations to some of our facilities,
approximately 20% of our employees worked reduced hours. In the UK
we utilised the Government's Coronavirus Job Retention Scheme and
received a total of GBP0.4m in furlough grants. In the US we
received an amount of $1.4m (GBP1.1m) under the Government's
Paycheck Protection Programme.
In accordance with FRC & ESMA best practice guidance we have
not separately identified the impact of the pandemic on the Group's
trading performance for the year. Instead we have included all
costs incurred and support received within the reported underlying
financial results of the business.
The Group's cash flows were temporarily supported by the UK
Government's scheme allowing businesses to defer sales and payroll
tax payments, however, all amounts owing were fully paid by the end
of the financial year.
The cash flow of the Group has been resilient during the
pandemic. We have not experienced any deterioration in our
collections performance nor has there been any increase in our
expected credit loss.
Order Book
As at 30 September 2020, the Group order book stood at GBP92.4m,
compared with GBP94.4m at the end of the 2019 financial year.
Excluding foreign exchange the order book was 0.8% higher. The book
to bill ratio for the business as a whole was 1.01 (six month
rolling average) as at 30 September 2020 (2019: 0.98). This
reflects an improving order intake trend in the latter stages of
the year.
Staff
The Group workforce decreased from 984 at 30 September 2019 to
902 at the end of September 2020. The reduction reflects the action
the business has taken to adjust to the lower levels of market
demand following the onset of the pandemic and initial releases of
staff from our Glenrothes site as part of the restructuring
programme .
Key Performance Indicators
The Group's objective is to deliver sustainable, long-term
growth in revenue and profits through the execution of the Board's
strategy.
In striving to achieve these strategic objectives, the main
financial performance measures monitored by the Board are:
Total revenue growth 2020 2019 2018
At actual exchange rates (5.5)% 3% 12%
------- ----- -----
At constant exchange rates (5.4)% - 16%
------- ----- -----
The Board is focused on driving long term revenue growth by
investing both organically and through acquisitions. The Group's
revenue measured at constant exchange rate declined by 5.4%
year-on-year reflecting the impact of the pandemic on our
Industrial and Aerospace & Defence sector partially offset by
the growth delivered by our Life Sciences/Biophotonics sector.
Target market revenue 2020 2019 2018
A&D (GBPm) 41.4 44.2 40.8
----- ----- -----
Life Sciences (GBPm) 25.9 24.1 11.2
----- ----- -----
The Group's target markets of A&D and Life Sciences provide
a route to sustainable growth, and a more diversified revenue base.
These markets also provide significant opportunities for G&H to
migrate up the value chain from materials and components to higher
value sub-assemblies, modules and systems in response to the trend
for our larger customers to outsource increasingly complex parts of
their business. Measured on a constant currency basis Life Sciences
revenues grew 7.7% thanks to strong demand for products from our
medical diagnostics business which more than offset the impact of
the pandemic on revenues for our medical laser products. In
A&D, revenues declined by 6.1% on a constant currency basis
reflecting the completion of deliveries on some material programmes
prior to the ramp up of deliveries on new secured programmes. Our
A&D order book at 30 September 2020 is strong and provides a
good underpin for revenue growth in the coming year.
Net debt analysis 2020 2019 2018
Net debt (GBPm) 14.7 14.3 10.6
----- ----- -----
In order to balance business risk with the investment needs of
the Company, management closely monitors and manages net debt.
Excluding the impact of the new lease standard, IFRS16, net debt
reduced by GBP7.8m in the year thanks to a reduction in the Group's
working capital levels and the benefit of favourable exchange rate
movement on the Group US$ denominated borrowing. This represents a
Net Debt : Adjusted EBITDA ratio of c.0.4x. Lease liabilities added
a further GBP8.2m within the total reported net debt of
GBP14.7m.
Earnings per share (EPS) 2020 2019 2018
Adjusted diluted EPS (pence) 30.2p 46.7p 56.5p
------ ------ ------
As a result of the continuing challenging trading environment in
the industrial laser sector and then the impact of the pandemic on
the Group's markets, adjusted diluted EPS fell 35.3%, from 46.7p to
30.2p.
The effect of adopting IFRS16 in the year was to reduce profit
before tax by GBP0.1m and to reduce adjusted diluted earnings per
share by 0.3p.
Group Income Statement
For the year ended 30 September 2020 (unaudited)
30 September 2020 30 September 2019
Note Underlying Non-underlying Total Underlying Non-underlying Total
(Note (Note
4) 4)
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Revenue 2 122,095 - 122,095 129,133 - 129,133
Cost of revenue (82,845) - (82,845) (84,231) - (84,231)
----------- --------------- --------- ----------- --------------- ---------
Gross profit 39,250 - 39,250 44,902 - 44,902
Research and development
Development (7,924) - (7,924) (7,074) - (7,074)
Sales and Marketing (7,440) - (7,440) (8,545) - (8,545)
Administration (13,759) (4,875) (18,634) (13,298) (8,228) (21,526)
Other income and
expenses 1,082 - 1,082 269 382 651
----------- --------------- --------- ----------- --------------- ---------
Operating profit 11,209 (4,875) 6,334 16,254 (7,846) 8,408
Finance income 16 818 834 21 - 21
Finance costs (1,473) (303) (1,776) (1,259) (1,218) (2,477)
----------- --------------- --------- ----------- --------------- ---------
Profit before income
tax expense 9,752 (4,360) 5,392 15,016 (9,064) 5,952
Income tax expense 3 (2,128) 518 (1,610) (3,332) 1,141 (2,191)
----------- --------------- --------- ----------- --------------- ---------
Profit for the
year 7,624 (3,842) 3,782 11,684 (7,923) 3,761
----------- --------------- --------- ----------- --------------- ---------
Basic earnings
per share 5 30.5p (15.4p) 15.1p 46.8p (31.7p) 15.1p
Diluted earnings
per share 5 30.2p (15.2p) 15.0p 46.7p (31.7p) 15.0p
----------- --------------- --------- ----------- --------------- ---------
Group Statement of Comprehensive Income
For the year ended 30 September 2020 (unaudited)
2020 2019
GBP000 GBP000
-------- -------
Profit for the year 3,782 3,761
Other comprehensive income / (expense)
- items that may be reclassified
subsequently to profit or loss
Gains on cash flow hedges 333 -
Currency translation differences (2,105) 2,549
Other comprehensive (expense) /
income for the year net of tax (1,772) 2,549
Total comprehensive income for the
year attributable to the shareholders
of Gooch & Housego PLC 2,010 6,310
-------- -------
Group Balance Sheet
For the year ended 30 September 2020 (unaudited)
2020 2019
GBP000 GBP000
--------- ---------
Non-current assets
Property, plant and equipment 38,741 39,621
Right of use assets 6,742 -
Intangible assets 54,624 58,598
Deferred income tax assets 1,432 1,539
--------- ---------
101,539 99,758
Current assets
Inventories 30,580 33,313
Trade and other receivables 26,298 33,190
Cash and cash equivalents 19,734 17,512
76,612 84,015
Current liabilities
Trade and other payables (17,971) (22,668)
Borrowings (64) (77)
Lease liabilities (1,832) -
Income tax liabilities (1,120) (1,114)
Deferred consideration (3,250) (4,750)
--------- ---------
(24,237) (28,609)
Net current assets 52,375 55,406
Non-current liabilities
Borrowings (26,211) (31,722)
Lease liabilities (6,364) -
Provision for other liabilities
and charges (1,692) (1,243)
Deferred income tax liabilities (6,294) (6,409)
Deferred consideration - (2,947)
(40,561) (42,321)
Net assets 113,353 112,843
--------- ---------
Shareholders' equity
Capital and reserves
attributable to equity shareholders
Called up share capital 5,008 5,008
Share premium account 16,000 16,000
Merger reserve 7,262 7,262
Cumulative translation reserve 7,675 9,780
Hedging reserve 333 -
Retained earnings 77,075 74,793
--------- ---------
Total equity 113,353 112,843
--------- ---------
Group Statement of Changes in Shareholders' Equity
For the year ended 30 September 2020
Note Called Share Cumulative
up share premium Merger Retained Hedging translation Total
capital account reserve earnings Reserve reserve equity
GBP000 GBP000 GBP000 GBP000 GBP000 GBP'000 GBP000
----------- ---------- ---------- ----------- ---------- -------------- ---------
At 1 October 2018 4,982 15,530 7,262 74,013 - 7,231 109,018
Profit for the
financial year - - - 3,761 - - 3,761
Other comprehensive
income for the
year - - - - - 2,549 2,549
----------- ---------- ---------- ----------- ---------- -------------- ---------
Total comprehensive
income for the
year - - - 3,761 - 2,549 6,310
----------- ---------- ---------- ----------- ---------- -------------- ---------
Dividends 6 - - - (2,849) - - (2,849)
Shares issued 26 470 - (19) - - 477
Fair value of
employee services - - - 191 - - 191
Tax debit relating
to share option
schemes - - - (304) - - (304)
Total contributions
by and
distributions
to owners of the
parent recognised
directly in equity 26 470 - (2,981) - - (2,485)
At 30 September
2019 5,008 16,000 7,262 74,793 - 9,780 112,843
At 1 October 2019 5,008 16,000 7,262 74,793 - 9,780 112,843
Profit for the
financial year - - - 3,782 - - 3,782
Other comprehensive
income / (expense)
for the year - - - - 333 (2,105) (1,772)
----------- ---------- ---------- ----------- ---------- -------------- ---------
Total comprehensive
income / (expense)
for the year - - - 3,782 333 (2,105) 2,010
----------- ---------- ---------- ----------- ---------- -------------- ---------
Dividends 6 - - - (1,803) - - (1,803)
Fair value of
employee services - - - 303 - - 303
Total contributions
by and
distributions
to owners of the
parent recognised
directly in equity - - - (1,500) - - (1,500)
At 30 September
2020 5,008 16,000 7,262 77,075 333 7,675 113,353
----------- ---------- ---------- ----------- ---------- -------------- ---------
Group Cash Flow Statement
For the year ended 30 September 2020 (unaudited)
2020 2019
GBP000 GBP000
--------- ---------
Cash flows from operating activities
Cash generated from operations 21,561 12,967
Income tax paid (1,119) (1,321)
--------- ---------
Net cash generated from operating
activities 20,442 11,646
--------- ---------
Cash flows from investing activities
Acquisition of subsidiaries, net
of cash acquired (4,750) (3,940)
Purchase of property, plant and
equipment (5,495) (5,792)
Sale of property, plant and equipment 353 1,480
Purchase of intangible assets (1,291) (1,620)
Interest received 846 21
Interest paid (1,399) (1,116)
Legal dispute settlement 1,580 -
--------- ---------
Net cash used in investing activities (10,156) (10,967)
--------- ---------
Cash flows from financing activities
Drawdown of borrowings 8,346 -
Repayment of borrowings (12,610) (60)
Principal elements of lease payments (1,583) (14)
Dividends paid to ordinary shareholders (1,803) (2,849)
Net cash used by financing activities (7,650) (2,923)
--------- ---------
Net increase / (decrease) in cash 2,636 (2,244)
Cash at beginning of the year 17,512 19,433
Exchange (losses) / gains on cash (414) 323
--------- ---------
Cash at the end of the year 19,734 17,512
--------- ---------
Notes to the preliminary report
1. Basis of preparation
The unaudited Preliminary Report has been prepared under the
historical cost convention and in accordance with International
Financial Reporting Standards ("IFRS") as adopted by the European
Union and interpretations in issue at 30 September 2020.
The Preliminary Report does not constitute statutory financial
statements within the meaning of section 434 of the Companies Act
2006 and has not been audited.
Comparative figures in the Preliminary Report for the year ended
30 September 2019 have been taken from the Group's audited
statutory financial statements on which the Group's auditors,
PricewaterhouseCoopers LLP, expressed an unqualified opinion. Those
financial statements have been restated as described below.
The accounting policies adopted are consistent with those of the
annual financial statements for the year ended 30 September 2019,
as described in those financial statements, except where newly
applicable accounting standards apply.
IFRS16 leases
IFRS 16 provides a single lease accounting model, requiring
lessees to recognize assets and liabilities for all leases.
On adoption of IFRS16, the group recognised lease liabilities in
relation to leases which had previously been classified as
operating leases under the principles of IAS17 "Leases". These
liabilities were measured at the present value of the remaining
lease payments, discounted using the lessee's incremental borrowing
rate as of 1 October 2019. The weighted average lessee's
incremental borrowing weight applied to the lease liabilities on 1
October 2019 was 3.33%
The group applied the modified retrospective approach to
transition. The effect of adopting the standard was to increase
liabilities (and net debt) by GBP9.4m at 1 October 2019. Right of
use assets of GBP9.6m were recognised on adoption of the new
standard whilst GBP0.2m previously held in other receivables
relating to lease deposits was eliminated on adoption of the new
Standard.
The standard had the effect of reducing profit before tax by
GBP0.1m over the prior year. This comprised an increase in
depreciation on right of use assets of GBP1.6m and an increase in
interest on lease liabilities of GBP0.4m. These were partially
offset by lease rental payments of GBP1.9m no longer being
recognised in the income statement.
There was no initial deferred tax effect on adoption of IFRS16.
Timing differences arising on IFRS16 in the year ended 30 September
2020 gave rise to a deferred tax asset of GBP0.4m.
In applying IFRS16 for the first time, the Group has used the
following practical expedients permitted by the standard:
-- accounting for operating leases with a remaining term of less
than 12 months as at 1 October 2019 as short-term leases; and
-- using hindsight in determining the lease term where the
contract contains options to extend or terminate the lease.
2. Segmental analysis
The Company's segmental reporting reflects the information that
management uses within the business. The business is divided into
three market sectors, being Aerospace & Defence, Life Sciences
/ Biophotonics and Industrial, together with the Corporate cost
centre .
The industrial business segment primarily comprises the
industrial laser market for use in the semiconductor and
microelectronic industries, but also includes other industrial
applications such as metrology, telecommunications and scientific
research.
Aerospace Life Sciences
& Defence / Bio-photonics Industrial Corporate Total
GBP000 GBP000 GBP000 GBP000 GBP000
For year ended 30
September 2020
-------------------------- ----------- -----------------
Revenue
Total revenue 41,390 27,578 60,280 - 129,248
Inter and intra-division - (1,684) (5,469) - (7,153)
-------------------------- ----------- ----------------- ----------- ---------- ----------
External revenue 41,390 25,894 54,811 - 122,095
Divisional expenses (37,295) (20,543) (48,004) 642 (105,200)
-------------------------- ----------- ----------------- ----------- ---------- ----------
EBITDA(1) 4,095 5,351 6,807 642 16,895
-------------------------- ----------- ----------------- ----------- ---------- ----------
EBITDA % 9.9% 20.7% 12.4% - 13.8%
Depreciation and
amortisation (2,554) (964) (3,636) (731) (7,885)
-------------------------- ----------- ----------------- ----------- ---------- ----------
Operating profit
before amortisation
of acquired intangible
assets 1,541 4,387 3,171 (89) 9,010
Amortisation of acquired
intangible assets - - - (2,676) (2,676)
-------------------------- ----------- ----------------- ----------- ---------- ----------
Operating profit 1,541 4,387 3,171 (2,765) 6,334
-------------------------- ----------- ----------------- ----------- ---------- ----------
Operating profit
margin % 3.7% 16.9% 5.8% - 5.2%
-------------------------- ----------- ----------------- ----------- ---------- ----------
Add back non-underlying
items and amortisation
of acquired intangibles 1,258 263 935 2,419 4,875
Adjusted operating
profit 2,799 4,650 4,106 (346) 11,209
-------------------------- ----------- ----------------- ----------- ---------- ----------
Adjusted profit margin
% 6.8% 18.0% 7.5% - 9.2%
-------------------------- ----------- ----------------- ----------- ---------- ----------
Finance costs (128) (32) (189) (593) (942)
-------------------------- ----------- ----------------- ----------- ---------- ----------
Profit before income
tax expense 1,413 4,355 2,982 (3,358) 5,392
-------------------------- ----------- ----------------- ----------- ---------- ----------
Aerospace Life Sciences
& Defence / Bio-photonics Industrial Corporate Total
GBP000 GBP000 GBP000 GBP000 GBP000
For year ended 30
September 2019
-------------------------- ----------- -----------------
Revenue
Total revenue 44,222 25,130 67,931 - 137,283
Inter and intra-division (19) (1,054) (7,077) - (8,150)
-------------------------- ----------- ----------------- ----------- ---------- ----------
External revenue 44,203 24,076 60,854 - 129,133
Divisional expenses (40,505) (18,538) (49,905) 3,391 (105,557)
-------------------------- ----------- ----------------- ----------- ---------- ----------
EBITDA(1) 3,698 5,538 10,949 3,391 23,576
-------------------------- ----------- ----------------- ----------- ---------- ----------
EBITDA % 8.4% 23.0% 18.0% - 18.3%
Depreciation and
amortisation (1,076) (649) (2,517) (978) (5,220)
-------------------------- ----------- ----------------- ----------- ---------- ----------
Operating profit
before amortisation
of acquired intangible
assets and goodwill
impairment 2,622 4,889 8,432 2,413 18,356
Amortisation of acquired
intangible assets
and goodwill impairment - - - (9,948) (9,948)
-------------------------- ----------- ----------------- ----------- ---------- ----------
Operating profit 2,622 4,889 8,432 (7,535) 8,408
-------------------------- ----------- ----------------- ----------- ---------- ----------
Operating profit
margin % 5.9% 20.3% 13.9% - 6.5%
-------------------------- ----------- ----------------- ----------- ---------- ----------
Add back non-underlying
items, amortisation
of acquired intangibles
and goodwill impairment 902 194 540 6,210 7,846
Adjusted operating
profit 3,524 5,083 8,972 (1,325) 16,254
-------------------------- ----------- ----------------- ----------- ---------- ----------
Adjusted profit margin
% 8.0% 21.1% 14.7% - 12.6%
-------------------------- ----------- ----------------- ----------- ---------- ----------
Finance costs - - - (2,456) (2,456)
-------------------------- ----------- ----------------- ----------- ---------- ----------
Profit before income
tax expense 2,622 4,889 8,432 (9,991) 5,952
-------------------------- ----------- ----------------- ----------- ---------- ----------
(1)EBITDA = Earnings before interest, tax, depreciation and
amortisation
Management have added back the amortisation of intangibles,
impairment of goodwill, restructuring costs, site closure costs,
charge / release in respect of contingent consideration and
transaction fees in the above analysis. This has been shown because
the Directors consider the analysis to be more meaningful excluding
the impact of these non-recurring expenses.
All of the amounts recorded are in respect of continuing
operations.
2. Segmental analysis (continued)
Analysis of net assets by location:
2020 2020 2020 2019 2019 2019
Assets Liabilities Net Assets Assets Liabilities Net Assets
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
-------- ------------ ----------- -------- ------------ -----------
United Kingdom 89,807 (41,676) 48,131 98,624 (57,859) 40,765
USA 86,824 (22,999) 63,825 84,196 (12,933) 71,263
Continental
Europe 738 (52) 686 260 (37) 223
Asia Pacific 782 (71) 711 693 (101) 592
-------- ------------ ----------- -------- ------------ -----------
178,151 (64,798) 113,353 183,773 (70,930) 112,843
-------- ------------ ----------- -------- ------------ -----------
For the year to 30 September 2020 non-current asset additions
were GBP5.1m (2019: GBP5.8m) for the UK and for the USA GBP3.1m
(2019: GBP1.7m). There were no additions to non-current assets in
respect of Europe (2019: GBPnil) or the Asia Pacific region (2019:
GBPnil). The value of non-current assets in the USA was GBP44.7m
(2019: GBP58.3m) and in the United Kingdom GBP39.3m (2019:
GBP41.4m). There were no non-current assets in Europe or the
Asia-Pacific region.
Analysis of revenue by destination:
2020 2019
GBP000 GBP000
-------- --------
United Kingdom 33,994 32,054
North America 45,554 50,097
Continental Europe 24,101 25,816
Asia Pacific and
Other 18,446 21,166
Total revenue 122,095 129,133
-------- --------
3. Income tax expense
Analysis of tax charge in the year
2020 2019
GBP000 GBP000
Current taxation
UK Corporation tax 1,089 1,756
Overseas tax 631 653
Adjustments in respect of prior (199) -
year tax charge
-------- --------
Total current tax 1,521 2,409
-------- --------
Deferred tax
Origination and reversal of temporary
differences (255) (218)
Adjustments in respect of prior 199 -
years
Change to UK tax rate 145 -
Total deferred tax 89 (218)
Income tax expense per income
statement 1,610 2,191
-------- --------
4. Non-underlying items
2020 2019
GBP000 GBP000
-------- --------
Included within administration
expenses
Amortisation of acquired intangible
assets 2,676 3,690
Restructuring and site closure
costs 2,609 1,355
Property litigation settlement (410) -
Goodwill impairment - 6,258
Adjustment to deferred consideration - (3,075)
-------- --------
4,875 8,228
-------- --------
Included within other income and
expense
Site closure costs - (382)
- (382)
-------------------------------------- ------
Included within net finance costs
Interest awarded in property litigation (818) -
settlement
Unwind of discount on deferred
consideration 303 1,218
(515) 1,218
------ ------
The restructuring and site closure costs incurred in the year
related to expenses arising from the project to establish the
Ilminster facility as our UK Precision Optics Centre of Excellence
and the resultant closure of our Glenrothes facility. The costs
recorded in the period principally comprised redundancy costs and
the write downs of both property, plant and equipment and
inventories of products which will be discontinued at the
completion of the project.
Restructuring costs incurred in the year ended 30 September 2019
related to expenses arising from the re-organisation of the
manufacturing centres, and the Group's commercial and business
development teams into a single integrated function.
In the year ended 30 September 2019, the Board took the decision
to impair the goodwill relating to the Boston and Baltimore cash
generating units by GBP3.6m and GBP2.6m respectively.
Site closure costs in FY19 related to the profit generated on
sale of the Group's Orlando facility (GBP0.8m), partially offset by
the costs associated with the closure of the Madison office
(GBP0.4m).
In March 2020 long running litigation with the landlord of our
Fremont facility was finally concluded. G&H was awarded a total
of $3.6m comprising damages, reimbursement of our costs and
interest arising from the landlord's non-performance in respect of
the lease and this amount was received in June 2020. The
reimbursement of costs and interest received of GBP1.2m were
treated as a non-underlying credit in the income statement whilst
the damages element of the award were credited against the right of
use asset held on the balance sheet.
The credit in respect of accrued contingent consideration
recorded in FY2019 related to StingRay (GBP0.5m). The final tranche
of the earn out was paid in FY19 but the maximum potential was not
achieved. In addition in FY2019, the full amount of the deferred
consideration in respect of Gould Fiber Optics was written back
(GBP2.6m).
5. Earnings per share
The calculation of earnings per 20p Ordinary Share is based on
the profit for the year using as a divisor the weighted average
number of Ordinary Shares in issue during the year. The weighted
average number of shares for the year ended 30 September is given
below:
2020 2019
Number of shares used for basic earnings
per share 25,039,519 24,936,438
Dilutive shares 174,664 141,696
Number of shares used for dilutive
earnings per share 25,214,183 25,078,134
----------- -----------
A reconciliation of the earnings used in the earnings per share
calculation is set out below:
2020 2019
pence pence
GBP000 per share GBP000 per share
------- ----------- -------- -----------
Basic earnings per share 3,782 15.1p 3,761 15.1p
Amortisation of acquired intangible
assets (net of tax) 2,279 9.1p 3,014 12.1p
Goodwill impairment (net of
tax) - - 5,337 21.4p
Release of accrued contingent
consideration (net of tax) - - (2,413) (9.7p)
Site closure costs (net of
tax) - - (317) (1.3p)
Restructuring costs (net of
tax) 2,218 8.9p 1,084 4.3p
Interest on deferred consideration 303 1.2p 1,218 4.9p
Property litigation settlement
(net of tax) (958) (3.8p) - -
------- ----------- -------- -----------
Total adjustments net of income
tax expense 3,842 15.4p 7,923 31.7p
------- ----------- -------- -----------
Adjusted basic earnings per
share 7,624 30.5p 11,684 46.8p
------- ----------- -------- -----------
Basic diluted earnings per
share 3,782 15.0p 3,761 15.0p
------- ----------- -------- -----------
Adjusted diluted earnings
per share 7,624 30.2p 11,684 46.7p
------- ----------- -------- -----------
Basic and diluted earnings per share before amortisation and
other adjustments has been shown because, in the opinion of the
Directors, it provides a useful measure of the trading performance
of the Group.
6. Dividends
2020 2019
GBP000 GBP000
-------- --------
Final 2019 dividend paid in 2020:
7.2p per share (Final 2018 dividend
paid in 2019: 7.1p per share) 1,803 1,772
2020 Interim dividend nil (2019:
4.3p) - 1,077
-------- --------
1,803 2,849
-------- --------
The Directors have not proposed a final dividend making the
total dividend paid and proposed in respect of the 2020 financial
year nil. (2019: 11.5p).
7. Cash generated from operating activities
Reconciliation of cash generated
from operations
2020 2019
GBP000 GBP000
-------- --------
Profit before income tax 5,392 5,952
Adjustments for:
- Amortisation of acquired intangible
assets 2,676 3,690
- Amortisation of other intangible
assets 984 672
- Profit on disposal of property,
plant and equipment (27) (741)
- Impairment of goodwill - 6,258
- Adjustment to accrued contingent
consideration - (3,075)
- Depreciation 6,901 4,548
- Share based payment charge 303 191
- Amounts claimed under the RDEC (315) (350)
- Finance income (834) (21)
- Finance costs 1,776 2,477
-------- --------
Total 11,464 13,649
Changes in working capital
- Inventories 2,042 (6,646)
- Trade and other receivables 6,812 2,729
- Trade and other payables (4,149) (2,717)
Total 4,705 (6,634)
Cash generated from operating activities 21,561 12,967
-------- --------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR WPGUUGUPUPUU
(END) Dow Jones Newswires
December 01, 2020 02:00 ET (07:00 GMT)
Gooch and Housego (AQSE:GHH.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Gooch and Housego (AQSE:GHH.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
